Meyka Pro banner
Moderna, Inc.

Stay Updated with the Latest Moderna, Inc. MRNA News in Real Time

Find MRNA news now at Meyka AI. Stay informed with the latest Moderna, Inc. stocks updates, including price news, market analysis, and expert insights.

MRNANASDAQ
HealthcareBiotechnology
$149.05
$25.33(14.53%)
U.S. Market is Open · 12:58
Bitcoin Price Today: BTC Soars 8% to $74,982 as Crypto Rally Explodes; Ethereum, XRP Surge
📅 4 hours ago

Bitcoin Price Today: BTC Soars 8% to $74,982 as Crypto Rally Explodes; Ethereum, XRP Surge

Bitcoin surged 8% to $74,982 on Friday, August 21, 2026, extending a powerful weekly rally. The cryptocurrency has now climbed nearly 20% since Monday, fueled by a surprise US Treasury policy shift. Ethereum jumped toward $2,300, gaining roughly 18% in 24 hours, while XRP surged past $1.25.  Total crypto market capitalization reached $2.56 trillion, up…

Read more 12
Tech Stocks to Watch: Alphabet Lifts 2026 Capex Forecast to $195B-205B
📅 6 hours ago

Tech Stocks to Watch: Alphabet Lifts 2026 Capex Forecast to $195B-205B

Alphabet is spending more to keep up with demand for artificial intelligence. On July 22, 2026, the Google parent raised its 2026 capital expenditure forecast to $195 billion-$205 billion, up from $180 billion-$190 billion. The increase comes as Google Cloud revenue jumped 82% to $24.8 billion in the second quarter. As AI demand drives higher…

Read more 12
Moderna Tumbles 23.5% After 177% Surge on Cancer Vaccine Win, August 21
📅 13 hours ago

Moderna Tumbles 23.5% After 177% Surge on Cancer Vaccine Win, August 21

Moderna stock fell 23.5% to $133.32 on August 21 after surging 177% the prior day on its cancer vaccine breakthrough with Merck. RSI hit record 92.21, signaling extreme overbought conditions.

Read more 12
Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21
📅 20 hours ago

Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21

Moderna stock jumps 122% after announcing its personalized mRNA melanoma vaccine met Phase 3 trial goals. The vaccine reduced cancer recurrence and spread when combined with Merck’s Keytruda.

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20
📅 1 day ago

Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20

Moderna jumps 177% and Merck rises 12% after their mRNA cancer vaccine meets Phase 3 endpoints for melanoma. The combo reduced cancer recurrence and spread in over 1,100 patients.

Read more 12
Crypto Prices Today: Bitcoin Hits $69,551, Ethereum Gains 17.74% as Hyperliquid Surges 20.97%
📅 1 day ago

Crypto Prices Today: Bitcoin Hits $69,551, Ethereum Gains 17.74% as Hyperliquid Surges 20.97%

Crypto prices surged sharply on Thursday, August 20, 2026, breaking weeks of sideways trading. Bitcoin jumped to $69,551, gaining roughly 8% in 24 hours. Ethereum climbed 17.74% to reclaim the $2,000 level, while Hyperliquid’s HYPE token surged 20.97%. The rally followed a surprise US Treasury announcement to double its long-dated bond buyback operations.  Total crypto…

Read more 12
NVDA Stock, AMD Stock, Micron and Broadcom Gain as AI Spending Estimates Rise
📅 1 day ago

NVDA Stock, AMD Stock, Micron and Broadcom Gain as AI Spending Estimates Rise

AI spending estimates are rising again, giving semiconductor stocks a fresh boost. On August 7, 2026, Goldman Sachs estimated global AI investment could reach about $1 trillion this year, above widely cited hyperscaler spending forecasts. That outlook is supporting demand for AI chips, memory and networking hardware. As a result, NVDA stock, AMD stock, Micron…

Read more 12
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
📅 1 day ago

Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20

Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
📅 1 day ago

Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.

Read more 12

MRNA News FAQ